Brian Hatch is an experienced Director of Bioproduct Research & Development at Eli Lilly, where they have focused on mammalian cell culture GMP and biopharmaceutical manufacturing since 2002. They have successfully led significant projects, including the design and qualification of a new GMP facility for gene therapy drug substances from 2021 to 2023, and contributed to the startup of commercial biopharmaceutical manufacturing facilities. Brian holds a BS in Biology and a BS in Microbiology from Kansas State University and previously worked as a Quality Control Microbiologist at Pfizer and in technical services at SAFC Biosciences/Sigma-Aldrich. Their extensive expertise encompasses process development, microbiological control, and the establishment of governing policies in the biopharmaceutical industry.
Location
Indianapolis, United States